earnings
confidence high
sentiment negative
materiality 0.80
Charles River Q2 revenue $973.1M (+6.4% YoY); non-GAAP EPS $2.77 (+6.1%); cuts FY22 guidance
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
2022-Q2 EPS reported
$3.94
revenue$1,887,060,000
- GAAP EPS $2.13 vs $1.72 Q2 2021; non-GAAP EPS $2.77 vs $2.61.
- Revenue $973.1M, organic growth 9.5% led by DSA and RMS segments.
- FY22 guidance cut: organic rev growth 10-12% (prev 12.5-14.5%), non-GAAP EPS $10.70-$10.95 (prev $11.50-$11.75).
- DSA segment revenue $591.9M (+12.9% organic); operating margin improved to 25.3% non-GAAP.
- Manufacturing segment revenue $194.8M (-1.5%); CDMO weakness offset by Biologics Testing growth.